All lobbying filings

THE MCMANUS GROUP

Lobbying for GILEAD SCIENCES, INC. · Client is a biopharmaceutical company that develops medicines in areas of unmet need.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

S 839
Safeguarding Honest Speech Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 2

Medicare/Medicaid

Support for EPIC Act - S. 839, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.